Organigram expects that edibles and infused products will be a major part of the future medical and recreational market for cannabis products. In anticipation of this transition in consumer demand, the Company intends to construct a purpose built infused products manufacturing facility on this newly acquired property. This facility will be in addition to the previously announced oils and extracts manufacturing infrastructure engineered and designed in collaboration with our partners in Colorado, TGS International.

Under the terms of the agreement, Organigram will acquire the 2.6-acre property, subject to certain terms and conditions and will have until January 16th to conduct confirmatory due diligence.

Full release can be viewed here.